公开(公告)号：US12006331B2

公开(公告)日：2024-06-11

申请号：US17862963

申请日：2022-07-12

Applicant: GENENTECH, INC.

Inventor： Samantha Alyson Green ,  Jessica Marie Grandner ,  Steven Thomas Staben ,  Neri Amara ,  Vishva M. Dixit ,  Elisia Villemure

IPC: C07D498/04 ,  A61K9/08 ,  A61K9/12 ,  A61K9/20 ,  A61K9/48 ,  A61K47/02 ,  A61K47/06 ,  A61K47/10 ,  A61K47/12 ,  C07D519/00 ,  C07F9/6561

CPC classification number: C07D498/04 ,  A61K9/08 ,  A61K9/12 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/2059 ,  A61K9/485 ,  A61K9/4858 ,  A61K9/4866 ,  A61K47/02 ,  A61K47/06 ,  A61K47/10 ,  A61K47/12 ,  C07D519/00 ,  C07F9/6561

Abstract: The invention provides a compound of formula (I):




or a prodrug thereof, or a pharmaceutically acceptable salt thereof, wherein R1 and R2 have any of the values described in the specification, as well as compositions comprising a compound of formula (I) or a prodrug thereof, or a pharmaceutically acceptable salt thereof. The compounds are agonists of glycolytic enzyme phosphofructokinase-1 liver type and are useful for treating diseases associated with the activity of glycolytic enzyme phosphofructokinase-1 liver type, such as cancer, diabetes, sepsis, and septic shock.

公开(公告)号：US20230016791A1

公开(公告)日：2023-01-19

申请号：US17821851

申请日：2022-08-24

Applicant: Genentech, Inc.

Inventor： Mark Edward Zak ,  Naomi S. Rajapaksa ,  Yun-Xing Cheng ,  Jessica Marie Grandner ,  Daniel G.M. Shore ,  Marian C. Bryan

IPC: C07D487/04 ,  A61P11/06 ,  A61K9/00 ,  A61K9/19

Abstract: wherein R1, R2, R3, R4, R5 and R6 are as defined herein, and salts thereof that are useful as JAK kinse inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.